profit from every $100 of sales.
$0$100
Q32 Bio
$9.33-0.11% today
+284.0% in 1 year
1-year low $1.931-year high $21.38
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $9.36 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Q32 Bio sold, what it kept, and what it did with the cash.
Sales went from $6.65 million in 2022 to $53.7 million in 2025, with $29.8 million of profit last year.
SalesProfit
Q32 Bio vs. similar companies
Q32 Bio grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Q32 Bio | 9.4× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Q32 Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 7 | -7 | 0 | 54 | |
| – | – | – | – | |
| -39 | -48 | -66 | 17 | |
| -39 | -48 | -45 | 31 | |
| -43 | -54 | -48 | 30 | |
| -3.59 | -4.51 | -6.58 | 2.42 | |
| – | – | – | – | |
| -589.8% | 725.5% | – | 31.5% | |
| -643.6% | 808.0% | – | 55.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 62 | 47 | 92 | 62 |
| Cash | 44 | 26 | 78 | 48 |
| Total debt | 45 | 51 | 19 | 15 |
| Total liabilities | 192 | 230 | 87 | 20 |
| -131 | -183 | 6 | 42 | |
| 12 | 12 | 10 | 12 | |
| – | – | -144.6% | 42.6% | |
| 32.8% | 29.4% | -841.1% | 71.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -19 | -68 | -34 | |
| 2 | 0 | 0 | – | |
| -13 | -19 | -68 | -34 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 4 | 5 |
Valuation
- 9.4×
- –
- –
- 6.3×
- 5.2×
- –
- 7.9×
- -12.0%
- 10.7%
- 0.0%
Profitability
- 99.5%
- 31.5%
- 55.5%
- 41.2%
- 43.7%
- -52.3%
- 230.7%
- 52.2%
- 40.4%
- 28.4%
Growth
- +100.7%
- –
- +50.5%
- –
- +1.1%
Financial health
- -1.1×
- 0.37
- 17.3%
- 28.1×
- 4.85
- 5.36
- 0.84
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 945
Top 9%of 870
Top 9%of 559
Top 6%of 867
Bottom 9%of 986
What analysts expect
- Average price target
- $13.00
- Range
- $13.00 – $13.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.54 | -0.52 | −3.8% |
| Mar 10, 2026 | 3.65 | -0.85 | +529.4% |
| Nov 13, 2025 | -0.60 | -1.39 | +56.8% |
| Aug 6, 2025 | -0.78 | -1.14 | +31.6% |
| May 8, 2025 | -0.90 | -1.23 | +26.8% |
| Mar 11, 2025 | -1.16 | -1.25 | +7.2% |
| Nov 7, 2024 | -1.46 | -1.41 | −3.5% |
| Aug 8, 2024 | -1.42 | -1.00 | −42.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
65Pass
Philip Fisher
74Pass
Peter Lynch
100Pass
Joel Greenblatt
92Pass
Charlie Munger
78Pass
Terry Smith
69Pass
Questions about Q32 Bio
Is Q32 Bio a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Q32 Bio AI analysis
What does Q32 Bio do?
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. It is in Biotechnology.
Does Q32 Bio pay a dividend?
No. Q32 Bio does not pay a dividend at the moment.
Is Q32 Bio stock halal?
Yes. Q32 Bio passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Q32 Bio stock done over the past year?
Up 284.0% over the past twelve months, to $9.33. It traded between $1.93 and $21.38 and is 56.4% below its high.
Who are Q32 Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Q32 Bio's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.